Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 2200
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Bcl2l1
Name: Bcl2-like 1
Acc ID: CHEBI:45716
Term: vorinostat
Definition: A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Chemical ID: MESH:C111237
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Bcl2l1decreases expressionEXP 6480464CTDvorinostat results in decreased expression of BCL2L1 proteinPMID:18310471
Bcl2l1multiple interactionsEXP 6480464CTD[vorinostat co-treated with MYC protein] results in decreased expression of BCL2L1 mRNA; [vorinostat co-treated with MYC protein] results in decreased expression of BCL2L1 proteinPMID:17331788
Bcl2l1decreases expressionISOBCL2L1 (Homo sapiens)6480464CTDvorinostat results in decreased expression of BCL2L1 mRNA; vorinostat results in decreased expression of BCL2L1 protein; vorinostat results in decreased expression of BCL2L1 protein alternative formPMID:15897598 PMID:16144943 PMID:17351739 PMID:19509267 PMID:20846458
Bcl2l1decreases response to substanceISOBcl2l1 (Mus musculus)6480464CTDBCL2L1 protein results in decreased susceptibility to vorinostatPMID:19060243
Bcl2l1decreases response to substanceISOBCL2L1 (Homo sapiens)6480464CTDBCL2L1 results in decreased susceptibility to vorinostatPMID:10597302
Bcl2l1increases expressionISOBCL2L1 (Homo sapiens)6480464CTDvorinostat results in increased expression of BCL2L1 mRNA alternative form; vorinostat results in increased expression of BCL2L1 protein alternative formPMID:17351739
Bcl2l1multiple interactionsISOBcl2l1 (Mus musculus)6480464CTDABT-737 inhibits the reaction [BCL2L1 protein results in decreased susceptibility to vorinostat]PMID:19060243
Bcl2l1multiple interactionsISOBCL2L1 (Homo sapiens)6480464CTD[(+)-JQ1 compound co-treated with vorinostat] results in decreased expression of BCL2L1 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; [vorinostat co-treated with Imatinib Mesylate] results in decreased expression of BCL2L1 protein; [vorinostat co-treated with TNFSF10 protein] results in decreased expression of BCLX protein; TNFSF10 protein promotes the reaction [vorinostat results in decreased expression of BCL2L1 mRNA]; TNFSF10 protein promotes the reaction [vorinostat results in decreased expression of BCL2L1 protein]; vorinostat inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]PMID:12446442 PMID:16377638 PMID:17351739 PMID:19509267 PMID:19643600 PMID:26390243
Go Back to source page   Continue to Ontology report